Omalizumab biosimilar, a cost effective option for patients with chronic urticaria: Our initial experience in two cases

---

Case Report

Author Details : Nidhi Sharma*, Ramanjit Singh, Anant Patil

Volume : 7, Issue : 1, Year : 2021

Article Page : 78-80

https://doi.org/10.18231/j.ijced.2021.015

Suggest article by email

Get Permission

---

Abstract

Chronic urticaria is a heterogenous skin condition. Second generation antihistamines are considered as first line treatment. In patients who do not respond to normal dose, second generation non-sedating antihistamines can be increased up to four fold. Some patients do not respond to higher dose of second generation non-sedating antihistamines. Omalizumab is an attractive option for such patients with chronic urticaria. However, cost of omalizumab is an important limiting factor for its wide use. Now with the availability of omalizumab biosimilar in India, it usage may be increased. We report two cases of difficult to treat chronic urticaria who responded to omalizumab biosimilar.

Keywords: Biosimilar, Chronic urticaria, Omalizumab, Response.

How to cite : Sharma N , Singh R , Patil A , Omalizumab biosimilar, a cost effective option for patients with chronic urticaria: Our initial experience in two cases. IP Indian J Clin Exp Dermatol 2021;7(1):78-80

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.